Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides

World Journal of Gastroenterology

Volumn 15, Issue 15, 2009, Pages 1805-1808

  Keeffe, Emmet B ^a,b,c,d   Rossignol, Jean François ^a,c  

^a Romark Institute for Medical Research   (United States)

^b The Romark Institute for Medical Research   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d Romark Laboratories LC   (United States)

Author keywords

Hepatitis C; Hepatitis C virus; Nitazoxanide

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NITAZOXANIDE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; THIAZOLIDINE DERIVATIVE; TIZOXANIDE; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HEPATITIS C; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; TABLET;

ANTIPARASITIC AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; PLACEBOS; THIAZOLES;

EID: 67651251216     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.1805     Document Type: Article

References (11)

1. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007; 67: 1947-1967
2. Elazar M, Liu M, McKenna S, Liu P, Gehrig EA, Elfert A, Puglisi J, Rossignol JF, Glenn JS. Nitazoxanide (NTZ) is an inducer of eIF2a and PKR phosphorylation [abstract]. Hepatology 2008; 48: 1151A
3. Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008; 77: 56-63
4. Schaninger T, Hong J, Luo GG. Nitazoxanide inhibits hepatitis C virus replication in vitro [abstract]. Hepatology 2008; 48: 756A
5. Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother 2008; 52: 4069-4071
6. Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008; 28: 574-580
7. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009; 136: 856-862
8. Rossignol JF, Elfert A, Keeffe EB. Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C: final report [abstract]. Hepatology 2008; 48: 344A-345A
9. Keeffe EB, Rossignol JF, Elfert A, Abdelatif S, Cavens L, Phong TLT. Controlled release tablet improves pharmacokinetics, viral kinetics and tolerability of nitazoxanide for treatment of chronic hepatitis C [abstract]. Hepatol Int 2009; 3: 49
10. Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol 2008; 3: 539-545
11. Kolozsi WZ, El-Gohary Y, Keeffe EB, Rossignol JF. Treatment of chronic hepatitis B (CHB) with nitazoxanide (NTZ) alone or NTZ plus adefovir (ADV) for two years with loss of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg): report of two cases [abstract]. Am J Gastroenterol 2008; 103: S150-S151